[G24-29] Futibatinib (cholangiocarcinoma) – Addendum to Project A24-66
Last updated 22.11.2024
Project no.:
G24-29
Commission:
Commission awarded on 10.10.2024 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Health Economics
Topic:
Cancer
Note:
If, in the course of the discussions on a commission of the G-BA, a need for further revision arises, IQWiG presents its report in the form of an addendum. The G-BA decides on the number of patients in the SHI target population.
DOI:
https://doi.org/10.60584/G24-29
| Project no. | Title | Status |
|---|---|---|
| A24-66 | Futibatinib (cholangiocarcinoma) – Benefit assessment according to § 35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2024-11-22 A G-BA decision was published.